The short version of thymosin beta-4 fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
=== Disease control intervention === Due to the suspicions that food markets could have played a role in the emergence of COVID-19, a group of US lawmakers, NIAID director Anthony Fauci, UNEP biodiversity chief Elizabeth Maruma Mrema, and CBCGDF secretary general Zhou Jinfeng called in April 2020 for the global closure of wildlife markets due to the potential for zoonotic diseases and risk to endangered species. In April 2021, the World Health Organization called for a total ban on the sale of live animals in food markets in order to prevent future pandemics. Planetary health studies have called for disease control intervention measures, in lieu of outlawing live-animal markets, to be implemented in markets. These include proposals for "standardised global monitoring of water, sanitation, and hygiene (WASH) conditions", which the World Health Organization announced in April 2020 that it was developing as requirements for markets to open. Other proposals include less homogeneous policies that are specialized for local social, cultural, and financial factors, as well as new proposed rapid assessment tools for monitoring the hygiene and biosecurity of live animal stalls in markets.
===== Inhibiting interferon response in some cancer cells ===== In HeLa cells SeV (in contrast to vesicular stomatitis virus) can counteract IFN-α pretreatment and keep a viral protein translation level similar to that in IFN-untreated cells.
Intussusceptive angiogenesis, also known as splitting angiogenesis, is the formation of a new blood vessel by splitting an existing blood vessel into two. Intussusception was first observed in neonatal rats. In this type of vessel formation, the capillary wall extends into the lumen to split a single vessel in two. There are four phases of intussusceptive angiogenesis. First, the two opposing capillary walls establish a zone of contact. Second, the endothelial cell junctions are reorganized and the vessel bilayer is perforated to allow growth factors and cells to penetrate into the lumen. Third, a core is formed between the 2 new vessels at the zone of contact that is filled with pericytes and myofibroblasts. These cells begin laying collagen fibers into the core to provide an extracellular matrix for growth of the vessel lumen. Finally, the core is fleshed out with no alterations to the basic structure. Intussusception is important because it is a reorganization of existing cells. It allows a vast increase in the number of capillaries without a corresponding increase in the number of endothelial cells. This is especially important in embryonic development as there are not enough resources to create a rich microvasculature with new cells every time a new vessel develops.
Sources: en.wikipedia.org
=== Use of paper microfluidics in blood grouping === Recently, paper microfluidics was used in the fabrication of numerous immunological tests. Khan et al. in 2010 investigated a blood typing device based on the principle that red blood cell agglutination, triggered by specific antigeninteraction, drastically decreases blood wicking and transport on paper or chromatographic media. The concept was exhibited with a paper-based microfluidic device prototype, made from a filter paper shaped to a central zone with three extending channels. Each channel is treated with a different solution of antibody (Epiclone Anti-A, Anti-B, and Anti-D). Since μPADs were purposely created for use in resource-shortage conditions, it is highly important to provide the capability to analyze real samples like non-pretreated human blood and urine. This device is constructed to analyze whole-blood samples, which is an important step to increase the user acceptance of paper-based microfluidic diagnostics. The analysis is based on the wicking behavior of blood or antibody mixture on paper. Mixing blood samples with immunoglobulin M antibodies, specific for each blood group, causes agglutination of the red blood cells (RBC) by polymer bridging upon adsorption on the corresponding RBC antigens, and chromatographic separation of sample on the certain channel of the device occurs. Simultaneously, separation doesn't happen on hands soaked in non-specific antibody and the blood sample is weakened as a uniform and stable solution.
== Ionic kosmotropes == Ionic kosmotropes tend to be small or have high charge density. Some ionic kosmotropes are CO2−3, SO2−4, HPO2−4, Mg2+, Li+, Zn2+ and Al3+. Large ions or ions with low charge density (such as Br−, I−, K+, Cs+) instead act as chaotropes. Kosmotropic anions are more polarizable and hydrate more strongly than kosmotropic cations of the same charge density. A scale can be established if one refers to the Hofmeister series or looks up the free energy of hydrogen bonding (
== Safety and regulations == PVDF is widely considered safe and ubiquitous used for water treatment, the food industry, and biocompatible devices like hernia meshes or internal devices. PVDF differs from PFAS in that alternating groups are hydrogen, making it less resilient to high temperatures, but also meaning that byproducts don't degrade into known hazardous PFAS. However, studies examining ecotoxity have shown that very high concentrations (up to 100 mg/L) may alter jellyfish behavior, while not being toxic to them. In the US, FDA regulations consider PVDF to be food safe, while US EPA water treatment regulations on PFAS have avoided placing limits on PVDF, while strictly limit concentrations of PFAS. PVDF was added to the Living Building Challenge (LBC) Red List in 2022. The Red List bans substances prevalent in the building industry that pose serious risks to human health and the environment from construction that seeks to meet the criteria of the Living Building Challenge (LBC). Proposed regulations in the EU aim to ban "any substance that contains at least one fully fluorinated methyl (-CF3) or methylene (-CF2-) carbon atom (without any H/Cl/Br/I attached to it)". Unless exemptions are made, the application of inconsistent and severe regulations may propose an existential risk to the industry.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.